You just read:

Novartis Announces Half of Eligible Ph+ CML-CP Patients Remain in Treatment-free Remission (TFR) Nearly Two Years After Stopping Tasigna® (nilotinib)

News provided by

Novartis UK

23 Jun, 2017, 07:40 BST